Publications

Found 5 results
Filters: Author is Di Liberto, Maurizio  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
C
Zhao X, Chen-Kiang S, Shetty S, Di Liberto M, Bodo J, Durkin L, Eng K, Elemento O, Smith MR, Hsi ED.  2015.  CCMCL1: a new model of aggressive mantle cell lymphoma.. Blood. 125(17):2730-2.
Chiron D, Di Liberto M, Martin P, Huang X, Sharman J, Blecua P, Mathew S, Vijay P, Eng K, Ali S et al..  2014.  Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.. Cancer Discov. 4(9):1022-35.
F
Jang J-Y, Hwang I, Pan H, Yao J, Alinari L, Imada E, Zanettini C, Kluk MJ, Wang Y, Lee Y et al..  2022.  A FOXO1-dependent transcription network is a targetable vulnerability of mantle cell lymphomas.. J Clin Invest. 132(24)
P
Brown-Burke F, Hwang I, Sloan S, Hinterschied C, Helmig-Mason JB, Long M, Chan WKeung, Prouty A, Chung J-H, Zhang Y et al..  2023.  PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma.. Blood Adv. 7(20):6211-6224.
Sloan SL, Brown F, Long M, Weigel C, Koirala S, Chung J-H, Pray B, Villagomez L, Hinterschied C, Sircar A et al..  2023.  PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma.. Blood. 142(10):887-902.